Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Novartis
Boehringer Ingelheim
US Army
Chubb
Julphar
Fuji
Teva
UBS
McKesson

Generated: February 23, 2018

DrugPatentWatch Database Preview

Horizon Pharma Company Profile

« Back to Dashboard

Summary for Horizon Pharma
International Patents:252
US Patents:52
Tradenames:7
Ingredients:7
NDAs:8

Drugs and US Patents for Horizon Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No 6,677,326 ➤ Sign Up Y ➤ Sign Up
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No 6,926,907 ➤ Sign Up Y ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 6,926,907 ➤ Sign Up Y ➤ Sign Up
Horizon Pharma DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes 8,449,910 ➤ Sign Up Y ➤ Sign Up
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No 9,186,332 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 6,369,085*PED ➤ Sign Up Y ➤ Sign Up
Horizon Pharma DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes 8,501,228 ➤ Sign Up ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 7,411,070*PED ➤ Sign Up Y ➤ Sign Up
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Horizon Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon Pharma Inc BUPHENYL sodium phenylbutyrate POWDER;ORAL 020573-001 Apr 30, 1996 4,457,942 ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 5,900,424*PED ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 5,714,504*PED ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 6,875,872*PED ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 5,900,424*PED ➤ Sign Up
Horizon Pharma Inc BUPHENYL sodium phenylbutyrate TABLET;ORAL 020572-001 May 13, 1996 4,457,942 ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 6,875,872*PED ➤ Sign Up
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 5,714,504*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HORIZON PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Solution 2.0% ➤ Subscribe 6/3/2014
➤ Subscribe Delayed-release Tablets 1 mg, 2 mg, and 5 mg ➤ Subscribe 11/26/2012
➤ Subscribe Topical Solution 1.5% ➤ Subscribe 7/11/2012
➤ Subscribe Tablets 800 mg/26.6 mg ➤ Subscribe 12/6/2011
➤ Subscribe Delayed-release Tablet 375 mg/20 mg and 500 mg/20 mg ➤ Subscribe 11/5/2010

Non-Orange Book US Patents for Horizon Pharma

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,511,039 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
6,677,455 Potassium salt of S-omeprazole ➤ Sign Up
8,466,175 Form of S-omeprazole ➤ Sign Up
9,750,708 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Sign Up
8,920,838 Delayed-release glucocorticoid treatment of rheumatoid disease ➤ Sign Up
8,206,741 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,364,439 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
9,801,824 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Sign Up
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Sign Up
6,747,155 Process ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Horizon Pharma Drugs

Supplementary Protection Certificates for Horizon Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00483 Netherlands ➤ Sign Up PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
2012000017 Germany ➤ Sign Up PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
2014 00013 Denmark ➤ Sign Up PRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906
C0041 France ➤ Sign Up PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
C/GB98/025 United Kingdom ➤ Sign Up PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
666 Luxembourg ➤ Sign Up PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
14/058 Ireland ➤ Sign Up PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
90006-4 Sweden ➤ Sign Up PRODUCT NAME: ACETYLSALICYLSYRA OCH ESOMEPRAZOLMAGNESIUMTRIHYDRAT; NAT. REG. NO/DATE: MTNR 44371 20110930; FIRST REG.: PT 5402359MFL 20110812
0 Finland ➤ Sign Up
5 Finland ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Argus Health
Colorcon
AstraZeneca
Dow
Citi
Federal Trade Commission
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot